Chemours (CC) Tops Q3 EPS by 17c; Offers Guidance

Chemours (NYSE: CC) reported Q3 EPS of $1.24, $0.17 better than the analyst estimate of $1.07. Revenue for the quarter came in at $1.78 billion versus the consensus estimate of $1.68 billion.

GUIDANCE:

As previously announced, Adjusted EBITDA for FY 2022 is expected to be between $1.40 billion and $1.45 billion. Free Cash Flow is expected to be greater than $575 million.

Mr. Newman concluded, \"Looking ahead, we believe we have the best assets, team, and strategy to continue to deliver strong performance through the economic cycle and create value for our stakeholders, despite the macroeconomic uncertainty. We remain focused on our four key priorities to enhance shareholder value, and on delivering another solid year of financial results.”

For earnings history and earnings-related data on Chemours (CC) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley Starts Adani Enterprises Ltd. (ADE:IN) at Overweight